Mortality rate and biomarker expression within COVID-19 patients who develop acute ischemic stroke: a systematic review and meta-analysis

OBJECTIVE: To describe the mortality difference between acute ischemic stroke (AIS) and non-AIS groups within COVID-19 patients. MATERIALS & METHODS: We included observational studies through September 2020 that categorized COVID-19 patients into two groups (with and without AIS). RESULTS: Eight...

Descripción completa

Detalles Bibliográficos
Autores principales: Yassin, Ahmed, Ghzawi, Ansam, Al-Mistarehi, Abdel-Hameed, El-Salem, Khalid, Y Benmelouka, Amira, M Sherif, Ahmed, BenhadjDahman, Nesrine, AlAdamat, Nameer, Jemel, Amine, Negida, Ahmed, Abdelmonem, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2021
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114837/
https://www.ncbi.nlm.nih.gov/pubmed/34254031
http://dx.doi.org/10.2144/fsoa-2021-0036
Descripción
Sumario:OBJECTIVE: To describe the mortality difference between acute ischemic stroke (AIS) and non-AIS groups within COVID-19 patients. MATERIALS & METHODS: We included observational studies through September 2020 that categorized COVID-19 patients into two groups (with and without AIS). RESULTS: Eight studies with a total sample size of 19,399 COVID-19 patients were included. The pooled risk difference showed that patients with COVID-19 who developed AIS had significantly higher mortality than those without AIS by a risk difference of 24% (95% CI: 0.10–0.39; p = 0.001). In two studies, the COVID-19+AIS group had significantly higher lymphocytes, procalcitonin and creatinine levels. CONCLUSION: Developing AIS significantly adds to the mortality of COVID-19. Timely interventions to manage those patients are strongly recommended.

Ejemplares similares